Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Bladder Cancer, January 2019

Free Subscription


Abstracts

Retrieve all available abstracts of the following 119 articles:
HTML format


 

Single Articles

  1. PRENDEVILLE S, Berney DM, Bubendorf L, Comperat E, et al
    Handling and Reporting of Pelvic Lymphadenectomy Specimens in Prostate and Bladder Cancer: A Web-based Survey by the European Network of Uropathologists (ENUP).
    Histopathology. 2019 Jan 3. doi: 10.1111/his.13818.
    Abstract    

    Abstract available

  2. SJODAHL G, Jackson Chelsea L, Bartlett J, Robert SD, et al
    Molecular Profiling In Muscle Invasive Bladder Cancer: More Than The Sum Of Its Parts.
    J Pathol. 2019 Jan 2. doi: 10.1002/path.5230.
    Abstract    

    Abstract available

  3. STUBENDORFF B, Wilhelm K, Posselt K, Catto J, et al
    A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancer.
    J Cancer Res Clin Oncol. 2019 Jan 2. pii: 10.1007/s00432-018-02829.
    Abstract    

    Abstract available

  4. VAN OSCH FHM, Vlaanderen J, Jochems SHJ, Bosetti C, et al
    Modeling the complex exposure history of smoking in predicting bladder cancer: a pooled analysis of 15 case-control studies.
    Epidemiology. 2018 Dec 26. doi: 10.1097/EDE.0000000000000964.
    Abstract    

    Abstract available

  5. TOKUNAGA K, Furuta A, Arizono S, Teramoto Y, et al
    Duodenal obstruction induced by retroperitoneal progression of bladder cancer: a report of two cases.
    Abdom Radiol (NY). 2019 Jan 1. pii: 10.1007/s00261-018-1874.
    Abstract    

    Abstract available

  6. GALLIOLI A, Boissier R, Territo A, Breda A, et al
    Towards the future of upper tract urothelial carcinoma surveillance: lessons learnt from bladder cancer urinary biomarkers.
    World J Urol. 2019 Jan 2. pii: 10.1007/s00345-018-2611.
    Abstract    



  7. ZHANG W, Zhang J, Zhang Z, Guo Y, et al
    Overexpression of Indoleamine 2,3-Dioxygenase 1 Promotes Epithelial-Mesenchymal Transition by Activation of the IL-6/STAT3/PD-L1 Pathway in Bladder Cancer.
    Transl Oncol. 2018;12:485-492.
    Abstract    

    Abstract available

  8. SMAL MP, Kuzhir TD, Savina NV, Nikitchenko NV, et al
    BER gene polymorphisms associated with key molecular events in bladder cancer.
    Exp Oncol. 2018;40:288-298.
    Abstract    

    Abstract available

  9. WU CH, Silvers CR, Messing EM, Lee YF, et al
    Bladder cancer extracellular vesicles drive tumorigenesis by inducing the unfolded protein response in endoplasmic reticulum of non-malignant cells.
    J Biol Chem. 2018 Dec 28. pii: RA118.006682. doi: 10.1074/jbc.RA118.006682.
    Abstract    

    Abstract available

  10. SALMASI A, Elashoff DA, Guo R, Upfill-Brown A, et al
    Urinary cytokine profile to predict response to intravesical BCG with or without HS-410 therapy in patients with non-muscle invasive bladder cancer.
    Cancer Epidemiol Biomarkers Prev. 2018 Dec 28. pii: 1055-9965.EPI-18-0893.
    Abstract    

    Abstract available

  11. TRIPATHI A, Plimack ER
    Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
    Curr Urol Rep. 2018;19:109.
    Abstract    

    Abstract available

  12. CEANGA AI, Ceanga M, Eveslage M, Herrmann E, et al
    Preoperative anemia and extensive transfusion during stay-in-hospital are critical for patient`s mortality: A retrospective multicenter cohort study of oncological patients undergoing radical cystectomy.
    Transfus Apher Sci. 2018;57:739-745.
    Abstract    

    Abstract available

  13. RODRIGUEZ-VIDA A, Bellmunt J
    Avelumab for the treatment of urothelial cancer.
    Expert Rev Anticancer Ther. 2018;18:421-429.
    Abstract    

    Abstract available

  14. CHEN A, Chong J, Si Q, Haines K, et al
    Robotic approach to resection of villous adenoma of the urachus: a case report and literature review.
    J Robot Surg. 2018;12:567-570.
    Abstract    

    Abstract available

  15. HUANG CJ, Lee CH, Chang YH, Won JG, et al
    Paravesical (urachal) paraganglioma (PGL) presenting as hypertensive crisis during micturition, mimicking bladder PGL.
    J Formos Med Assoc. 2018;117:247-249.
    Abstract    



  16. ONISHI T, Sekito S, Shibahara T, Uchida K, et al
    The role of continuous saline bladder irrigation after transurethral resection in patients with high-grade non-muscle-invasive bladder cancer.
    Scand J Urol. 2019 Jan 10:1-4. doi: 10.1080/21681805.2018.1548502.
    Abstract    

    Abstract available

  17. CHEN R, Zhou X, Liu J, Huang G, et al
    Relationship between the expression of PD-1/PD-L1 and (18)F-FDG uptake in bladder cancer.
    Eur J Nucl Med Mol Imaging. 2019 Jan 9. pii: 10.1007/s00259-018-4208.
    Abstract    

    Abstract available

  18. MATUSZEWSKI M, Szymanska B, Dlugosz A, Malkiewicz B, et al
    Preliminary Evaluation of the Diagnostic Usefulness of Uroplakin 2 with an Assessment of the Antioxidant Potential of Patients with Bladder Cancer.
    Biomed Res Int. 2018;2018:8693297.
    Abstract    

    Abstract available

  19. ELMUSSAREH M, Simonsen PC, Young M, Kingo PS, et al
    Correlation between organ-specific co-morbidities and complications in bladder cancer patients undergoing radical cystectomy.
    Scand J Urol. 2019 Jan 9:1-6. doi: 10.1080/21681805.2018.1531921.
    Abstract    

    Abstract available

  20. ABDEL-RAHMAN O
    Population-based validation of the National Comprehensive Cancer Network recommendations for baseline imaging for bladder cancer: a case for routine baseline bone scan?
    J Comp Eff Res. 2019 Jan 9. doi: 10.2217/cer-2018-0113.
    Abstract    

    Abstract available

  21. NASRAZADANI M, Maracy MR, Dreassi E, Mahaki B, et al
    Mapping of Stomach, Colorectal, and Bladder Cancers in Iran, 2004-2009: Applying Bayesian Polytomous Logit Model.
    Int J Prev Med. 2018;9:104.
    Abstract    

    Abstract available

  22. DANIELSSON G, Malmstrom PU, Jahnson S, Wijkstrom H, et al
    Bladder health in patients treated with BCG instillations for T1G2-G3 bladder cancer - a follow-up five years after the start of treatment.
    Scand J Urol. 2019 Jan 8:1-8. doi: 10.1080/21681805.2018.1538162.
    Abstract    

    Abstract available

  23. WANG JR, Liu B, Zhou L, Huang YX, et al
    MicroRNA-124-3p suppresses cell migration and invasion by targeting ITGA3 signaling in bladder cancer.
    Cancer Biomark. 2018 Dec 27. pii: CBM182000. doi: 10.3233/CBM-182000.
    Abstract    

    Abstract available

  24. ZHANG LF, Ren KW, Zuo L, Zou JG, et al
    VEGF gene rs3025039C/T and rs833052C/A variants are associated with bladder cancer risk in Asian descendants.
    J Cell Biochem. 2019 Jan 4. doi: 10.1002/jcb.28324.
    Abstract    

    Abstract available

  25. CHEN JB, Zhu YW, Guo X, Yu C, et al
    Microarray expression profiles analysis revealed lncRNA OXCT1-AS1 promoted bladder cancer cell aggressiveness via miR-455-5p/JAK1 signaling.
    J Cell Physiol. 2019 Jan 4. doi: 10.1002/jcp.28037.
    Abstract    

    Abstract available

  26. RYU H, Jin H, Ho JN, Bae J, et al
    Suberoylanilide Hydroxamic Acid Can Re-sensitize a Cisplatin-Resistant Human Bladder Cancer.
    Biol Pharm Bull. 2019;42:66-72.
    Abstract    

    Abstract available

  27. WANG L, Xin F, Lin N, Wang Y, et al
    Metallothioneins may be a potential prognostic biomarker for tumors: A Prisma-compliant meta-analysis.
    Medicine (Baltimore). 2018;97:e13786.
    Abstract    

    Abstract available

  28. WANG K, Zhou H, Lu Y, Lu Q, et al
    ALK-negative urachal inflammatory myofibroblastic tumor in an elderly female: A case report.
    Medicine (Baltimore). 2018;97:e13619.
    Abstract    

    Abstract available

  29. ZHOU Y, Guan H, Fu Y, Mao L, et al
    The impact of pre-existing cancer on survival of prostate cancer patients: A population-based study.
    Medicine (Baltimore). 2018;97:e13479.
    Abstract    

    Abstract available

  30. YUK HD, Kim JK, Jeong CW, Kwak C, et al
    Differences in Pathologic Results of Repeat Transurethral Resection of Bladder Tumor (TURBT) according to Institution Performing the Initial TURBT: Comparative Analyses between Referred and Nonreferred Group.
    Biomed Res Int. 2018;2018:9432606.
    Abstract    

    Abstract available

  31. TUNG MC, Wen YC, Wang SS, Lin YW, et al
    Dopamine receptor D2 genetic variations is associated with the risk and clinicopathological variables of urothelial cell carcinoma in a Taiwanese population.
    Int J Med Sci. 2018;15:1187-1193.
    Abstract    

    Abstract available

  32. PAVONE C, Candela L, Fontana D, Simonato A, et al
    Postoperative complications and 90-day mortality in radical cystectomy in high-risk patients: A monocentric retrospective observational study.
    Urologia. 2018;85:111-117.
    Abstract    

    Abstract available

  33. FANG T, Liu DD, Ning HM, Dan Liu, et al
    Modified citrus pectin inhibited bladder tumor growth through downregulation of galectin-3.
    Acta Pharmacol Sin. 2018;39:1885-1893.
    Abstract    

    Abstract available

  34. MCGRATH JS, Daneshmand S
    Readmission Following Radical Cystectomy: A Ray of Light in the "Black Box"?
    Eur Urol Focus. 2018;4:718-719.
    Abstract    



  35. SILVA-SMITH R, Sussman DA
    Co-occurrence of Lynch syndrome and juvenile polyposis syndrome confirmed by multigene panel testing.
    Fam Cancer. 2018;17:87-90.
    Abstract    

    Abstract available

  36. BAO F, Deng Y, Dai Q
    ACID: Association Correction for Imbalanced Data in GWAS.
    IEEE/ACM Trans Comput Biol Bioinform. 2018;15:316-322.
    Abstract    

    Abstract available

  37. PALMISANO F, Gadda F, Spinelli MG, Maggioni M, et al
    Symplastic glomus tumor of the urinary bladder treated by robot-assisted partial cystectomy: a case report and literature review.
    Urologia. 2018;85:130-132.
    Abstract    

    Abstract available

  38. AMARA CS, Ambati CR, Vantaku V, Piyarathna DWB, et al
    Serum metabolic profiling identified a distinct metabolic signature in Bladder Cancer Smokers: A key metabolic enzymes associated with patient survival.
    Cancer Epidemiol Biomarkers Prev. 2019 Jan 14. pii: 1055-9965.EPI-18-0936.
    Abstract    

    Abstract available

  39. MONTEIRO-REIS S, Lobo J, Henrique R, Jeronimo C, et al
    Epigenetic Mechanisms Influencing Epithelial to Mesenchymal Transition in Bladder Cancer.
    Int J Mol Sci. 2019;20.
    Abstract    

    Abstract available

  40. XIE X, Pan J, Han X, Chen W, et al
    Downregulation of microRNA-532-5p promotes the proliferation and invasion of bladder cancer cells through promotion of HMGB3/Wnt/beta-catenin signaling.
    Chem Biol Interact. 2019 Jan 10. pii: S0009-2797(18)31262.
    Abstract    

    Abstract available

  41. MOROZUMI K, Mitsuzuka K, Takai Y, Katsumata Y, et al
    Intraoperative hypothermia is a significant prognostic predictor of radical cystectomy especially for stage II muscle-invasive bladder cancer.
    Medicine (Baltimore). 2019;98:e13962.
    Abstract    

    Abstract available

  42. LIU Y, Wu X, Wang G, Hu S, et al
    CALD1, CNN1, and TAGLN identified as potential prognostic molecular markers of bladder cancer by bioinformatics analysis.
    Medicine (Baltimore). 2019;98:e13847.
    Abstract    

    Abstract available

  43. CRITSELIS E, Rava M, Marquez M, Lygirou V, et al
    Diagnostic and prognostic performance of Secreted Protein Acidic and Rich in Cysteine (SPARC) assay for detecting primary and recurrent urinary bladder cancer.
    Proteomics Clin Appl. 2019 Jan 11:e1800148. doi: 10.1002/prca.201800148.
    Abstract    

    Abstract available

  44. WUJANTO C, Tey J, Chia D, Ho F, et al
    Radical radiotherapy in older patients with muscle invasive bladder cancer.
    J Geriatr Oncol. 2019 Jan 7. pii: S1879-4068(18)30302.
    Abstract    

    Abstract available

  45. NIWA N, Matsumoto K, Ide H
    The clinical implication of gamma globulin levels in patients with nonmuscle-invasive bladder cancer.
    Urol Oncol. 2019 Jan 7. pii: S1078-1439(18)30552.
    Abstract    

    Abstract available

  46. SONG D, Jiao W, Gao Z, Liu N, et al
    Inflammatory myofibroblastic tumor of urinary bladder with severe hematuria: A Case report and literature review.
    Medicine (Baltimore). 2019;98:e13987.
    Abstract    

    Abstract available

  47. THIBAULT C
    Bladder Cancer Treatment (PDQ(R)): Patient Version
    Bull Cancer. 2018;105 Suppl 1:S43-S49.
    Abstract    

    Abstract available

  48. HUANG Z, Xiao H, Lu X, Yan W, et al
    Enhanced photo/chemo combination efficiency against bladder tumor by encapsulation of DOX and ZnPC into in situ-formed thermosensitive polymer hydrogel.
    Int J Nanomedicine. 2018;13:7623-7631.
    Abstract    

    Abstract available

  49. KHAN FM, Gupta SK, Wolkenhauer O
    Integrative workflows for network analysis.
    Essays Biochem. 2018;62:549-561.
    Abstract    

    Abstract available

  50. DENG J, Peng M, Wang Z, Zhou S, et al
    Novel application of metformin combined with targeted drugs on anticancer treatment.
    Cancer Sci. 2019;110:23-30.
    Abstract    

    Abstract available

  51. BOSSERMAN AJ, Dai D, Lu Y
    Imaging Characteristics of a Bladder Wall Paraganglioma.
    Clin Nucl Med. 2019;44:66-67.
    Abstract    

    Abstract available

  52. DELAUNE T, Bernard F, Matres-Lorenzo L, Bernarde A, et al
    Radical cystectomy and subsequent ureterohysterostomy in a bitch.
    Vet Surg. 2018;47:1106-1111.
    Abstract    

    Abstract available

  53. ELAWDY MM, Osman Y, Taha DE, El-Halwagy S, et al
    Coincidental Bladder Cuff Transitional Cell Carcinoma in Nephroureterectomy Specimens: Risk Factors, Prognosis and Clinical Implementation.
    Urol J. 2018;15:256-260.
    Abstract    

    Abstract available

  54. XU Z, Zhang Q, Luh F, Jin B, et al
    Overexpression of the ASPM gene is associated with aggressiveness and poor outcome in bladder cancer.
    Oncol Lett. 2019;17:1865-1876.
    Abstract    

    Abstract available

  55. LU JJ, Su YW, Wang CJ, Li DF, et al
    Semaphorin 4D promotes the proliferation and metastasis of bladder cancer by activating the PI3K/AKT pathway.
    Tumori. 2019 Jan 24:300891618811280. doi: 10.1177/0300891618811280.
    Abstract    

    Abstract available

  56. RAJA SA, Abbas S, Shah STA, Tariq A, et al
    Increased expression levels of Syntaxin 1A and Synaptobrevin 2/Vesicle-Associated Membrane Protein-2 are associated with the progression of bladder cancer.
    Genet Mol Biol. 2019 Jan 21:0. doi: 10.1590/1678-4685-GMB-2017-0339.
    Abstract    

    Abstract available

  57. GUO CC, Czerniak B
    Bladder Cancer in the Genomic Era.
    Arch Pathol Lab Med. 2019 Jan 23. doi: 10.5858/arpa.2018-0329.
    Abstract    

    Abstract available

  58. QIU F, Zhang MR, Zhou Z, Pu JX, et al
    lncRNA MIR503HG functioned as a tumor suppressor and inhibited cell proliferation, metastasis and epithelial-mesenchymal transition in bladder cancer.
    J Cell Biochem. 2019 Jan 22. doi: 10.1002/jcb.28373.
    Abstract    

    Abstract available

  59. GUPTA M, Milbar N, Tema G, Pederzoli F, et al
    Impact of intravesical therapy for non-muscle invasive bladder cancer on the accuracy of urine cytology.
    World J Urol. 2019 Jan 23. pii: 10.1007/s00345-018-02624.
    Abstract    

    Abstract available

  60. YEE CH, Zheng Z, Shuman L, Yamashita H, et al
    Maintenance of the bladder cancer precursor urothelial hyperplasia requires FOXA1 and persistent expression of oncogenic HRAS.
    Sci Rep. 2019;9:270.
    Abstract    

    Abstract available

  61. TAARNHOJ GA, Johansen C, Pappot H
    Quality of life in bladder cancer patients receiving medical oncological treatment; a systematic review of the literature.
    Health Qual Life Outcomes. 2019;17:20.
    Abstract    

    Abstract available

  62. RODRIGUES D, Pinto J, Araujo AM, Jeronimo C, et al
    GC-MS Metabolomics Reveals Distinct Profiles of Low- and High-Grade Bladder Cancer Cultured Cells.
    Metabolites. 2019;9.
    Abstract    

    Abstract available

  63. DAGA M, Pizzimenti S, Dianzani C, Cucci MA, et al
    Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression.
    Phytomedicine. 2018;56:156-164.
    Abstract    

    Abstract available

  64. AMR S, Wolpert BJ, St George DM, James I, et al
    Body mass index modifies bladder cancer risk associated with low estrogen exposure among Egyptian women after menopause.
    Cancer Causes Control. 2019 Jan 21. pii: 10.1007/s10552-019-1131.
    Abstract    

    Abstract available

  65. WANG F, Chen HG, Zhang RY, Jin D, et al
    Diffusion kurtosis imaging to assess correlations with clinicopathologic factors for bladder cancer: a comparison between the multi-b value method and the tensor method.
    Eur Radiol. 2019 Jan 21. pii: 10.1007/s00330-018-5977.
    Abstract    

    Abstract available

  66. GIRARD A, Rouanne M, Taconet S, Radulescu C, et al
    Integrated analysis of (18)F-FDG PET/CT improves preoperative lymph node staging for patients with invasive bladder cancer.
    Eur Radiol. 2019 Jan 21. pii: 10.1007/s00330-018-5959.
    Abstract    

    Abstract available

  67. BLACK P, Gontero P
    SIU-ICUD consultation on bladder cancer 2018.
    World J Urol. 2019 Jan 21. pii: 10.1007/s00345-018-2601.
    Abstract    



  68. ZHAO S, Xie Q, Yang R, Wang J, et al
    High prevalence of secondary bladder cancer in men on radiotherapy for prostate cancer: evidence from a meta-analysis.
    Cancer Manag Res. 2019;11:587-598.
    Abstract    

    Abstract available

  69. WU J, Li W, Ning J, Yu W, et al
    Long noncoding RNA UCA1 targets miR-582-5p and contributes to the progression and drug resistance of bladder cancer cells through ATG7-mediated autophagy inhibition.
    Onco Targets Ther. 2019;12:495-508.
    Abstract    

    Abstract available

  70. MIERZEJEWSKA P, Gawlik-Jakubczak T, Jablonska P, Czajkowski M, et al
    Nicotinamide metabolism alterations in bladder cancer: Preliminary studies.
    Nucleosides Nucleotides Nucleic Acids. 2019.
    Abstract    

    Abstract available

  71. JIN S, Wang B, Zhu Y, Dai W, et al
    Log Odds Could Better Predict Survival in Muscle-Invasive Bladder Cancer Patients Compared with pN and Lymph Node Ratio.
    J Cancer. 2019;10:249-256.
    Abstract    

    Abstract available

  72. CHEN Z, Chen X, Xie R, Huang M, et al
    DANCR Promotes Metastasis and Proliferation in Bladder Cancer Cells by Enhancing IL-11-STAT3 Signaling and CCND1 Expression.
    Mol Ther. 2019 Jan 9. pii: S1525-0016(19)30004.
    Abstract    

    Abstract available

  73. FU YR, Chen F, Luo Y, Yi YF, et al
    Nanoscale bubble ultrasound contrast agents-mediated suicide gene therapy system, Nanoscale bubble-LV5-YCD-TK/GCV/5-FC, effectively inhibits bladder cancer cell growth.
    Eur Rev Med Pharmacol Sci. 2019;23:75-86.
    Abstract    

    Abstract available

  74. KWAN ML, Kushi LH, Danforth KN, Roh JM, et al
    The Be-Well Study: a prospective cohort study of lifestyle and genetic factors to reduce the risk of recurrence and progression of non-muscle-invasive bladder cancer.
    Cancer Causes Control. 2019 Jan 17. pii: 10.1007/s10552-019-1130.
    Abstract    

    Abstract available

  75. WANG X, Wang H, Song Y
    Clinical efficacy and mechanism of Pralatrexate combined with Palbociclib Isethionate in treatment of bladder cancer patients.
    Oncol Lett. 2019;17:201-208.
    Abstract    

    Abstract available

  76. YE G, Kan S, Chen J, Lu X, et al
    Puerarin in inducing apoptosis of bladder cancer cells through inhibiting SIRT1/p53 pathway.
    Oncol Lett. 2019;17:195-200.
    Abstract    

    Abstract available

  77. HOU Y
    MiR-506 inhibits cell proliferation, invasion, migration and epithelial-to-mesenchymal transition through targeting RWDD4 in human bladder cancer.
    Oncol Lett. 2019;17:73-78.
    Abstract    

    Abstract available

  78. EISSA S, Safwat M, Matboli M, Zaghloul A, et al
    Measurement of Urinary Level of a Specific Competing endogenous RNA network (FOS and RCAN mRNA/ miR-324-5p, miR-4738-3p, /lncRNA miR-497-HG) Enables Diagnosis of Bladder Cancer.
    Urol Oncol. 2019 Jan 14. pii: S1078-1439(18)30518.
    Abstract    

    Abstract available

  79. FURUYA H, Chan OTM, Pagano I, Zhu C, et al
    Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model.
    J Transl Med. 2019;17:29.
    Abstract    

    Abstract available

  80. MISTRETTA FA, Carrion DM, Nazzani S, Vasquez JL, et al
    Bladder recurrence of primary upper tract urinary carcinoma following nephro-ureterectomy, and risk of upper urinary tract recurrence after ureteral stent positioning in patients with primary bladder cancer: a contemporary non-systematic review of the
    Minerva Urol Nefrol. 2019 Jan 17. pii: S0393-2249.19.03311.
    Abstract    

    Abstract available

  81. DUNN JA, Jefferson K, MacDonald D, Iqbal G, et al
    LOW SERUM 25-HYDROXYVITAMIN D IS ASSOCIATED WITH INCREASED BLADDER CANCER RISK: A SYSTEMATIC REVIEW AND EVIDENCE OF A POTENTIAL MECHANISM.
    J Steroid Biochem Mol Biol. 2019 Jan 14. pii: S0960-0760(18)30620.
    Abstract    

    Abstract available

  82. RUSSO V, Roperto F, Taulescu M, De Falco F, et al
    Expression of the feline leukemia virus subgroup C receptors in normal and neoplastic urothelium of the urinary bladder of cattle associated with bovine papillomavirus infection.
    Vet Microbiol. 2019;229:147-152.
    Abstract    

    Abstract available

  83. KRASNOW RE, Rodriguez D, Nagle RT, Mossanen M, et al
    The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies.
    Urol Oncol. 2018;36:500.
    Abstract    

    Abstract available

  84. YAP SA, Brunson A, Pugashetti N, M P H RDC, et al
    Immediate intravesical chemotherapy for low-grade bladder tumors in California: An underutilized practice and its impact on recurrence.
    Urol Oncol. 2018;36:498.
    Abstract    

    Abstract available

  85. COX RM, Magi-Galluzzi C, McKenney JK
    Immunohistochemical Pitfalls in Genitourinary Pathology: 2018 Update.
    Adv Anat Pathol. 2018;25:387-399.
    Abstract    

    Abstract available

  86. RADES D, Sondermann L, Motisi L, Janssen S, et al
    Prognostic Factors and a Survival Score in Patients Irradiated for Metastatic Epidural Spinal Cord Compression from Urothelial Carcinoma Cancer of the Bladder.
    Anticancer Res. 2018;38:6841-6846.
    Abstract    

    Abstract available

  87. BOERI L, Soligo M, Frank I, Boorjian SA, et al
    Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-centre expe
    BJU Int. 2019 Jan 8. doi: 10.1111/bju.14612.
    Abstract    

    Abstract available

  88. BAJIC P, Wolfe AJ, Gupta GN
    Old Instillations and New Implications in Bladder Cancer: The Urinary Microbiome and Intravesical BCG.
    BJU Int. 2019 Jan 21. doi: 10.1111/bju.14683.
    Abstract    

    Abstract available

  89. D'ANDREA D, Soria F, Zehetmayer S, Gust KM, et al
    Diagnostic accuracy, clinical utility and influence on decision making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer.
    BJU Int. 2019 Jan 17. doi: 10.1111/bju.14673.
    Abstract    

    Abstract available

  90. VANTAKU V, Donepudi SR, Piyarathna DWB, Sekhar Amara C, et al
    Large-scale profiling of serum metabolites in African American and European American patients with bladder cancer reveals metabolic pathways associated with patient survival.
    Cancer. 2019 Jan 2. doi: 10.1002/cncr.31890.
    Abstract    

    Abstract available

  91. COLE AP, Fletcher SA, Berg S, Nabi J, et al
    Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?
    Cancer. 2019 Jan 11. doi: 10.1002/cncr.31926.
    Abstract    

    Abstract available

  92. YU C, Liu Z, Chen Q, Li Y, et al
    Nkx2.8 Inhibits Epithelial-Mesenchymal Transition in Bladder Urothelial Carcinoma via Transcriptional Repression of Twist1.
    Cancer Res. 2018;78:1241-1252.
    Abstract    

    Abstract available

  93. CAPURSO G, Archibugi L, Tessieri L, Petrone MC, et al
    Focal immune-related pancreatitis occurring after treatment with programmed cell death 1 inhibitors: a distinct form of autoimmune pancreatitis?
    Eur J Cancer. 2018;95:123-126.
    Abstract    



  94. ROUANNE M, Betari R, Radulescu C, Goubar A, et al
    Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer.
    Eur J Cancer. 2019;108:111-119.
    Abstract    

    Abstract available

  95. GIANNARINI G, Crestani A, Ficarra V
    Re: Stenting Prior to Cystectomy Is an Independent Risk Factor for Upper Urinary Tract Recurrence.
    Eur Urol. 2018;74:395-396.
    Abstract    



  96. SZABADOS B, van Dijk N, Tang YZ, van der Heijden MS, et al
    Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.
    Eur Urol. 2018;73:149-152.
    Abstract    

    Abstract available

  97. YUH B, Chan K, Wilson T
    Robotic Cystectomy-Moving from Innovation to Measurable Impact.
    Eur Urol. 2018;74:472-473.
    Abstract    

    Abstract available

  98. ZUIVERLOON TCM, Theodorescu D
    Re: Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Eur Urol. 2019 Jan 17. pii: S0302-2838(18)31024.
    Abstract    



  99. DUGUE PA, Brinkman MT, Hodge AM, Bassett JK, et al
    Dietary intake of nutrients involved in one-carbon metabolism and risk of urothelial cell carcinoma: A prospective cohort study.
    Int J Cancer. 2018;143:298-306.
    Abstract    

    Abstract available

  100. TURNER MC, Gracia-Lavedan E, Cirac M, Castano-Vinyals G, et al
    Ambient air pollution and incident bladder cancer risk: updated analysis of the Spanish Bladder Cancer Study.
    Int J Cancer. 2019 Jan 17. doi: 10.1002/ijc.32136.
    Abstract    

    Abstract available

  101. MIYATA Y, Matsuo T, Sakai H
    Editorial Comment from Dr Miyata et al. to Impact of serum sodium concentration on survival outcomes in patients with invasive bladder cancer without metastasis treated by cystectomy.
    Int J Urol. 2019 Jan 22. doi: 10.1111/iju.13893.
    Abstract    

    Abstract available

  102. ATALA A
    Re: Identification of MicroR-106b as a Prognostic Biomarker of p53-Like Bladder Cancers by ActMiR.
    J Urol. 2019;201:231.
    Abstract    



  103. CHANG SS
    Re: Analysis of T1 Bladder Cancer on Biopsy and Transurethral Resection Specimens: .
    J Urol. 2019;201:225-226.
    Abstract    



  104. EBRAHIMI H, Amini E, Pishgar F, Moghaddam SS, et al
    Global, Regional, and National Burden of Bladder Cancer, 1990 - 2016: Results from the Global Burden of Disease Study 2016.
    J Urol. 2019 Jan 25. doi: 10.1097/JU.0000000000000025.
    Abstract    

    Abstract available

  105. CHANG SS
    Re: Long-Term Survival Outcomes with Intravesical Nanoparticle Albumin-Bound Paclitaxel for Recurrent Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Guerin Therapy.
    J Urol. 2019 Jan 15. doi: 10.1097/JU.0000000000000097.
    Abstract    



  106. CHANG SS
    Re: Next-Generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
    J Urol. 2019 Jan 15. doi: 10.1097/01.JU.0000553308.83315.
    Abstract    



  107. ATALA A
    Re: LNMAT1 Promotes Lymphatic Metastasis of Bladder Cancer via CCL2 Dependent Macrophage Recruitment.
    J Urol. 2019 Jan 15. doi: 10.1097/01.JU.0000553307.75692.
    Abstract    



  108. ZHU J, Huang G, Hua X, Li Y, et al
    CD44s is a crucial ATG7 downstream regulator for stem-like property, invasion, and lung metastasis of human bladder cancer (BC) cells.
    Oncogene. 2019 Jan 11. pii: 10.1038/s41388-018-0664.
    Abstract    

    Abstract available

  109. CHENG M, Sheng L, Gao Q, Xiong Q, et al
    The m(6)A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-kappaB/MYC signaling network.
    Oncogene. 2019 Jan 18. pii: 10.1038/s41388-019-0683.
    Abstract    

    Abstract available

  110. FERRO M, Vartolomei MD, Cantiello F, Lucarelli G, et al
    High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study.
    Urol Int. 2018;101:7-15.
    Abstract    

    Abstract available

  111. BEN BAHRIA-SEDIKI I, Chebil M, Sampaio C, Martel-Frachet V, et al
    Prognostic Value of Soluble Death Receptor Ligands in Patients with Transitional Cell Carcinoma of Bladder.
    Urol Int. 2018;100:476-484.
    Abstract    

    Abstract available

  112. GIERTH M, Zeman F, Denzinger S, Vetterlein MW, et al
    Influence of Body Mass Index on Clinical Outcome Parameters, Complication Rate and Survival after Radical Cystectomy: Evidence from a Prospective European Multicentre Study.
    Urol Int. 2018;101:16-24.
    Abstract    

    Abstract available

  113. RAYN KN, Ritchie C, Folio LR, Stamatakis L, et al
    Bilateral Ureteroenteric Strictures: A Case of the "Reverse 7".
    Urology. 2018;118:e3-e4.
    Abstract    

    Abstract available

  114. BAJIC P, Wolfe AJ, Gupta GN
    The Urinary Microbiome: Implications in Bladder Cancer Pathogenesis and Therapeutics.
    Urology. 2019 Jan 4. pii: S0090-4295(19)30006.
    Abstract    

    Abstract available

  115. GONZALEZ AN, Lipsky MJ, Li G, Rutman MP, et al
    The prevalence of bladder cancer during cystoscopy for asymptomatic microscopic hematuria.
    Urology. 2019 Jan 21. pii: S0090-4295(19)30073.
    Abstract    

    Abstract available

  116. LOH-DOYLE JC, Ashrafi A, Nazemi A, Ghodoussipour S, et al
    Dual Prosthetic Implantation After Radical Cystoprostatectomy and Neobladder: Outcomes of the Inflatable Penile Prosthesis and Artificial Urinary Sphincter in Bladder Cancer Survivors.
    Urology. 2019 Jan 18. pii: S0090-4295(19)30065.
    Abstract    

    Abstract available

  117. YOSHINO T, Miyazaki J, Kojima T, Kandori S, et al
    Cationized liposomal keto-mycolic acids isolated from Mycobacterium bovis bacillus Calmette-Guerin induce antitumor immunity in a syngeneic murine bladder cancer model.
    PLoS One. 2019;14:e0209196.
    Abstract    

    Abstract available

  118. APOLLO A, Ortenzi V, Scatena C, Zavaglia K, et al
    Molecular characterization of low grade and high grade bladder cancer.
    PLoS One. 2019;14:e0210635.
    Abstract    

    Abstract available

  119. BYUN SJ, Park W, Cho KH, Cho J, et al
    A multi-institutional study of bladder-preserving therapy for stage II-IV bladder cancer: A Korean Radiation Oncology Group Study (KROG 14-16).
    PLoS One. 2019;14:e0209998.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;